Press release
Recurrent Glioblastoma Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight | Sichuan Baili Pharmaceutical Co., Ltd., Cordgenics LLC, Genexine Inc., Ascletis Pharmaceuticals Co., Ltd., Cantex Pharmaceuticals, P
Recurrent Glioblastoma Market
Discover which therapies are expected to grab the Recurrent Glioblastoma Market Share @ Recurrent Glioblastoma Market Outlook- https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Recurrent Glioblastoma Market Report
• In March 2025, Cordgenics LLC announced a clinical study is to confirm the utility of chemosensitivity tumor testing on cancer stem cells (ChemoID) as a predictor of clinical response in poor prognosis malignant brain tumors such as recurrent glioblastoma (GBM).
• In March 2025, CarThera organized a study of a randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma.
• In March 2025, Acerta Pharma BV announced a study was designed to evaluate the efficacy and safety of acalabrutinib in subjects with recurrent glioblastoma multiforme (GBM) who had progressed after one or two prior systemic treatment regimens.
• In March 2025, VBI Vaccines Inc. conducted a study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
• The increase in Recurrent Glioblastoma Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Recurrent Glioblastoma Market is anticipated to witness growth at a considerable CAGR.
• The leading Recurrent Glioblastoma Companies such as Sichuan Baili Pharmaceutical Co., Ltd., Cordgenics LLC, Genexine Inc., Ascletis Pharmaceuticals Co., Ltd., Cantex Pharmaceuticals, PharmAbcine, CASI Pharmaceuticals Inc., AstraZeneca, NovoCure Ltd, InSightec, and others.
• Promising Recurrent Glioblastoma Pipeline Therapies such as Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab and others.
Stay ahead in the Recurrent Glioblastoma Therapeutics Market with DelveInsight's Strategic Report @ Recurrent Glioblastoma Market Outlook- https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Recurrent Glioblastoma Epidemiology Segmentation in the 7MM
The epidemiology section of Recurrent Glioblastoma offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Recurrent Glioblastoma Epidemiology trends @ Recurrent Glioblastoma Prevalence- https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Recurrent Glioblastoma Drugs Market
The Recurrent Glioblastoma Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Recurrent Glioblastoma signaling in Recurrent Glioblastoma are likely to uncover new therapeutic targets and further expand treatment options for patients.
Recurrent Glioblastoma Treatment Market Landscape
The Recurrent Glioblastoma treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Recurrent Glioblastoma has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Recurrent Glioblastoma treatment guidelines, visit @ Recurrent Glioblastoma Treatment Market Landscape- https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Recurrent Glioblastoma Market Outlook
The report's outlook on the Recurrent Glioblastoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Recurrent Glioblastoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Recurrent Glioblastoma drug and late-stage pipeline therapy.
Recurrent Glioblastoma Drugs Uptake
The drug chapter of the Recurrent Glioblastoma report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Recurrent Glioblastoma.
Major Recurrent Glioblastoma Companies
Sichuan Baili Pharmaceutical Co., Ltd., Cordgenics LLC, Genexine Inc., Ascletis Pharmaceuticals Co., Ltd., Cantex Pharmaceuticals, PharmAbcine, CASI Pharmaceuticals Inc., AstraZeneca, NovoCure Ltd, InSightec
Learn more about the FDA-approved drugs for Recurrent Glioblastoma @ Drugs for Recurrent Glioblastoma Treatment- https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Recurrent Glioblastoma Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Recurrent Glioblastoma Companies-Sichuan Baili Pharmaceutical Co., Ltd., Cordgenics LLC, Genexine Inc., Ascletis Pharmaceuticals Co., Ltd., Cantex Pharmaceuticals, PharmAbcine, CASI Pharmaceuticals Inc., AstraZeneca, NovoCure Ltd, InSightec
• Recurrent Glioblastoma Pipeline Therapies- Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab and others.
• Recurrent Glioblastoma Market Dynamics: Recurrent Glioblastoma Market Drivers and Barriers
• Recurrent Glioblastoma Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Recurrent Glioblastoma Drugs in development @ Recurrent Glioblastoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Recurrent Glioblastoma Executive Summary
3. Competitive Intelligence Analysis for Recurrent Glioblastoma
4. Recurrent Glioblastoma: Market Overview at a Glance
5. Recurrent Glioblastoma: Disease Background and Overview
6. Patient Journey
7. Recurrent Glioblastoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Recurrent Glioblastoma Unmet Needs
10. Key Endpoints of Recurrent Glioblastoma Treatment
11. Recurrent Glioblastoma Marketed Products
12. Recurrent Glioblastoma Emerging Therapies
13. Recurrent Glioblastoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Recurrent Glioblastoma Market Outlook
16. Access and Reimbursement Overview of Recurrent Glioblastoma
17. KOL Views
18. Recurrent Glioblastoma Market Drivers
19. Recurrent Glioblastoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
List of Top Selling Market Research Reports in 2025
Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Recurrent Glioblastoma Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight | Sichuan Baili Pharmaceutical Co., Ltd., Cordgenics LLC, Genexine Inc., Ascletis Pharmaceuticals Co., Ltd., Cantex Pharmaceuticals, P here
News-ID: 3923512 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Glioblastoma
Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Adv …
Which drivers are expected to have the greatest impact on the over the glioblastoma multiforme market's growth?
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population,…
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
* DelveInsight's Glioblastoma pipeline report depicts…
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market…
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest…
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
DelveInsight's Recurrent Glioblastoma…
Revolutionizing Glioblastoma Treatment Strategies: A Deep Dive into the Glioblas …
The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements.
Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players…
